## 3 Results
\begin{table}
\begin{tabular}{c c c c} \hline  & **CC (N = 79)** & **CG (N = 75)** & **GG (N = 18)** \\ \hline Mild Asthma & 40/79 (50.6\%) & 41/75 (54.7\%) & 6/18 (33.3\%) \\ \hline Moderate-to-severe asthma & 39/79 (49.4\%) & 34/75 (45.3\%) & 12/18 (66.7\%) \\ \hline Age (years) & 58.4 \(\pm\) 14.1 & 56.9 \(\pm\) 14.4 & 64.3 \(\pm\) 10.3 \\ \hline Gender (F) & 47/79 (59.5\%) & 53/75 (70.7\%) & 9/18 (50.0\%) \\ \hline BMI (Kg/m\({}^{2}\)) & 26.7 \(\pm\) 5.3 & 26.4 \(\pm\) 5.7 & 28.2 \(\pm\) 5.0 \\ \hline Current smokers (\(\geq\)10 PY) & 24/79 (30.4\%) & 14/75 (18.7\%) & 4/18 (22.2\%) \\ \hline Former smokers (\(\geq\)10 PY) & 1/79 (1.3\%) & 0/75 (0.0\%) & 0/18 (0.0\%) \\ \hline Atopy & 50/79 (63.3\%) & 43/75 (57.3\%) & 7/18 (61.1\%) \\ \hline Poly-sensitization & 43/50 (86.0\%) & 34/43 (79.1\%) & 4/7 (57.1\%) \\ \hline Asthma exacerbations per year & 1.3 \(\pm\) 1.3 & 1.2 \(\pm\) 1.6 & 1.8 \(\pm\) 1.9 \\ \hline FE phenotype & 26/79 (32.9\%) & 20/75 (26.7\%) & 8/18 (44.4\%) \\ \hline Serum IgE (kU/L) & 327.0 \(\pm\) 515.0 & 252.9 \(\pm\) 373.9 & 111.7 \(\pm\) 96.3 \\ \hline Serum IgE >100 kV/L & 42/64 (65.6\%) & 32/59 (54.2\%) & 3/12 (25.0\%) * \\ \hline F\({}_{\rm E}\)NO (ppb) & 35.9 \(\pm\) 26.6 & 40.4 \(\pm\) 27.0 & 42.5 \(\pm\) 31.4 \\ \hline \end{tabular}
\end{table} 
Table 4: Descriptive statistics in the asthmatic population stratified for the rs41423247 polymorphism. \begin{table}
\begin{tabular}{c c c c} \hline  & **All Population (N = 172)** & **Mild Asthma (N = 87)** & **Moderate-Severe** \\ Blood eosinophils \textgreater{}300 cells/\(\mu\)L & 70/163 (42.9\%) & 29/82 (35.4\%) & 41/81 (50.6\%) * \\ \hline ICS/day (\(\mu\)g BDP-HFA) & 330.2 \(\pm\) 210.3 & 160.9 \(\pm\) 81.2 & 503.5 \(\pm\) 152.3 *** \\ \hline LABA & 127/172 (73.8\%) & 44/87 (50.6\%) & 83/85 (97.6\%) *** \\ \hline LAMA & 23/172 (13.4\%) & 0/87 (0.0\%) & 23/85 (27.0\%) *** \\ \hline OCS (\(\geq\)6 months/year) & 5/173 (2.9\%) & 0/87 (0.0\%) & 5/85 (5.9\%) * \\ \hline Omalizumab & 17/172 (9.9\%) & 2/87 (2.3\%) & 15/85 (17.6\%) ** \\ \hline Mepolizumab & 4/172 (2.3\%) & 1/87 (1.1\%) & 3/85 (3.5\%) \\ \hline Osteoporosis & 10/172 (5.8\%) & 3/87 (3.4\%) & 7/85 (8.2\%) \\ \hline Obesity & 42/172 (24.4\%) & 18/87 (20.7\%) & 24/85 (28.2\%) \\ \hline GERD & 47/172 (27.3\%) & 20/87 (23.0\%) & 23/85 (27.1\%) \\ \hline AERD & 34/172 (19.8\%) & 14/87 (16.1\%) & 20/85 (23.5\%) \\ \hline Persistent Rhinitis & 145/172 (84.3\%) & 75/87 (86.2\%) & 70/85 (82.3\%) \\ \hline CRSsNP & 36/172 (20.9\%) & 17/87 (19.5\%) & 19/85 (22.3\%) \\ \hline CRSwNP & 25/172 (14.5\%) & 8/87 (9.2\%) & 17/85 (20.0\%) \\ \hline Cardiopathy & 14/172 (8.1\%) & 4/88 (4.6\%) & 10/85 (11.8\%) \\ \hline \end{tabular}  
* Use of BDP-HFA \(\geq\) 400 ug/day plus LABA; AERD: aspirin-exacerbated respiratory disease; BDP-HFA: clometthasone dipropionate hydrofluoroalkane; CRSSNP: chronic rhinosusitis without nasal polyposis; CRswNP: chronic rhinosinusitis with nasal polyposis; FE phenotypes: frequent exacerbate phenotype \(\geq\)2 severe asthma exacerbations per year with OCS burst; GERD: gastro–esophageal reflux disease; LABA: long-acting beta-agonists; LAMA: long-acting muscarinic antagonists; ICS: inhaled corticosteroids; OCS: oral corticosteroids;
* \(p\) \(<\) 0.05, *
* \(p\)\(<\) 0.01, *
* \(p\)\(<\) 0.001, and **
* \(p\)\(<\) 0.001 vs. mild asthma.  
\end{table} 
Table 3: _Cont._